Table 1 Baseline characteristics in the overall population and in subgroups defined by avelumab start date.
Overall population (N = 773) | Start of avelumab maintenance | ||
|---|---|---|---|
2021 (n = 289) | 2022 or later (n = 484) | ||
Age | |||
Median (IQR) [range], years | 74 (69–79) [40–98] | 74 (69–79) [44–89] | 74 (69–80) [40–98] |
< 65 years, n (%) | 106 (13.7) | 35 (12.1) | 71 (14.7) |
65 to < 75 years, n (%) | 309 (40.0) | 127 (43.9) | 182 (37.6) |
75 to < 80 years, n (%) | 169 (21.9) | 69 (23.9) | 100 (20.7) |
≥ 80 years, n (%) | 189 (24.5) | 58 (20.1) | 131 (27.1) |
Sex, n (%) | |||
Male | 576 (74.5) | 219 (75.8) | 357 (73.8) |
Female | 197 (25.5) | 70 (24.2) | 127 (26.2) |
Body mass index | |||
Median (IQR), kg/m2 | 22.9 (20.9–25.0) | 23.2 (21.3–25.2) | 22.7 (20.7–24.8) |
< 18.5 kg/m2, n (%) | 58 (7.5) | 20 (6.9) | 38 (7.9) |
18.5 to < 25 kg/m2, n (%) | 508 (65.7) | 184 (63.7) | 324 (66.9) |
≥ 25 kg/m2, n (%) | 189 (24.5) | 77 (26.6) | 112 (23.1) |
Unknown | 18 (2.3) | 8 (2.8) | 10 (2.1) |
Smoking status, n (%) | |||
Yes | 350 (45.3) | 138 (47.8) | 212 (43.8) |
No | 307 (39.7) | 105 (36.3) | 202 (41.7) |
Unknown | 116 (15.0) | 46 (15.9) | 70 (14.5) |
Primary tumor site, n (%) | |||
Bladder | 463 (59.9) | 178 (61.6) | 285 (58.9) |
Renal pelvis and ureter | 330 (42.7) | 121 (41.9) | 209 (43.2) |
Urethra | 6 (0.8) | 1 (0.3) | 5 (1.0) |
Metastatic site, n (%) | |||
Lung | 148 (19.1) | 56 (19.4) | 92 (19.0) |
Liver | 48 (6.2) | 24 (8.3) | 24 (5.0) |
Bone | 102 (13.2) | 45 (15.6) | 57 (11.8) |
Peritoneum | 19 (2.5) | 8 (2.8) | 11 (2.3) |
Other | 39 (5.0) | 17 (5.9) | 22 (4.5) |
Hospital scale, n (%) | |||
< 200 beds | 11 (1.4) | 3 (1.0) | 8 (1.7) |
200 to < 500 beds | 351 (45.4) | 113 (39.1) | 238 (49.2) |
≥ 500 beds | 411 (53.2) | 173 (59.9) | 238 (49.2) |
Designated cancer care hospital, n (%) | |||
Yes | 692 (89.5) | 265 (91.7) | 427 (88.2) |
No | 81 (10.5) | 24 (8.3) | 57 (11.8) |
